Pasquale M D, Campbell J M, Magnant C M
Department of Surgery, Georgetown University Hospital, Washington, District of Columbia 20007.
Surg Gynecol Obstet. 1992 May;174(5):408-10.
There has been an increasing need for safe and efficient means of establishing vascular access in the patient with cancer. Recently, the use of percutaneous cannulation of the central veins, using guidewires, venous dilators and tearaway introducer sheaths, has become a popular method of establishing such access. The greatest concerns with the use of such catheters include sepsis, thrombus formation within the vein and catheter malfunction. The current study compared the incidence of these complications with Groshong (Cath Tech CV catheters with Groshong valve) and Hickman (Bard Access Systems vascular access catheters) catheters. Although there was no significant difference in septic complications and thrombus formation between the two groups, there was a significant (p less than 0.05) difference in catheter malfunction. Patients with Hickman catheters experienced significantly less problems with one way intermittent and one way catheters than did patients with Groshong catheters. We conclude that, based on catheter function, the Hickman catheter appears to be a more favorable alternative when compared with the Groshong catheter in the patient with cancer.
在癌症患者中,对安全、有效的建立血管通路方法的需求日益增加。最近,使用导丝、静脉扩张器和可撕开式导入鞘经皮穿刺中心静脉,已成为建立此类通路的常用方法。使用此类导管最令人担忧的问题包括败血症、静脉内血栓形成和导管故障。本研究比较了使用Groshong(带Groshong瓣膜的Cath Tech CV导管)和Hickman(巴德血管通路系统血管通路导管)导管时这些并发症的发生率。虽然两组之间的败血症并发症和血栓形成没有显著差异,但导管故障存在显著(p小于0.05)差异。与使用Groshong导管的患者相比,使用Hickman导管的患者在单向间歇性和单向导管方面遇到的问题明显更少。我们得出结论,基于导管功能,在癌症患者中,与Groshong导管相比,Hickman导管似乎是更有利的选择。